Efficacy and safety of the academic anti‐CD19 chimeric antigen receptor T‐cell product varnimcabtagene autoleucel for the treatment of relapsed/refractory follicular lymphoma

Authors:

Abstract
We report the outcome of patients with relapsed/refractory (R/R) follicular lymphoma (FL) treated with varnimcabtagene autoleucel (var‐cel), an academic anti‐CD19 chimeric antigen receptor (CAR) T‐cell product. Patients were included in the CART19‐BE‐01 clinical trial and a compassionate use program. Twenty‐seven patients with FL were treated. Cytokine release syndrome (any grade) occurred in 55% of patients (4% Grade ≥3). Only 1 case (4%) of Grade 1 neurotoxicity was documented. The objective response rate was 100% at Day +100 (93% complete response rate), and the 3‐year duration of response was 78%. The 3‐year progression‐free survival and overall survival were 78% and 81%, respectively. All patients developed B‐cell aplasia, and the 3‐year incidence of B‐cell recovery was 17%. In conclusion, patients with R/R FL treated with var‐cel obtained excellent disease control, with prolonged CAR T‐cell survival and manageable toxicity. This trial was registered as NCT03144583.

This publication has 32 references indexed in Scilit: